HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Activation of coagulation in C57BL/6 mice given verotoxin 2 (VT2) and the effect of co-administration of LPS with VT2.

Abstract
To obtain better insight into the pathogenesis of verotoxin-producing Escherichia coli-associated diseases, in this study, we explored the effect of verotoxin 2 (VT2) on coagulation in an animal model. After being given VT2 (50 ng/kg, lethal dose), C57BL/6 mice showed progressively increasing expression of TF mRNA in the kidney and brain and elevated plasma levels of thrombin-antithrombin III complex (TAT), normotest, fibrinogen, and PAI-1 paralleling the disease course over 24 hours; platelet counts were decreased at 48 hours with hemorrhage in the kidney and brain. Co-administration of lipopolysaccharide (LPS, 0.5 mg/kg) with VT2 (50 ng/kg) exhibited more prominant and/or prolonged increase in not only expression of TF and PAI-1 mRNAs in the kidney and brain but also plasma levels of TAT, fibrinogen, and PAI-1 and was associated with more remarkable hemorrhage in the tissues. Although VT2 (5 ng/kg) was not a lethal dose, co-administration of LPS (0.5 mg/kg) with VT2 (5 ng/kg) enhanced the susceptibility to VT2, resulting in more prolonged elevation of TAT levels during the first 24 hours than that in the LPS group and a second elevation at 72 hours, followed by death. Plasma IL-1beta level reached a maximum at 24 hours after VT2 (50 ng/kg) injection prior to the increase in TAT levels, whereas the increase in TNFalpha level immediately after injection was associated with the increase in PAI-1 mRNA. These observations indicate that the activation of coagulation by VT2 may occur through a mechanism different from that used by LPS, since plasma TAT levels rose in the mice immediately after LPS injection and returned to normal over 36 hours.
AuthorsJ Sugatani, T Igarashi, M Munakata, Y Komiyama, H Takahashi, N Komiyama, T Maeda, T Takeda, M Miwa
JournalThrombosis research (Thromb Res) Vol. 100 Issue 1 Pg. 61-72 (Oct 01 2000) ISSN: 0049-3848 [Print] United States
PMID11053618 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Cytokines
  • Lipopolysaccharides
  • Plasminogen Activator Inhibitor 1
  • RNA, Messenger
  • Shiga Toxin 2
  • antithrombin III-protease complex
  • Antithrombin III
  • Fibrinogen
  • Thromboplastin
  • Peptide Hydrolases
Topics
  • Animals
  • Antithrombin III (drug effects)
  • Blood Coagulation (drug effects)
  • Blood Coagulation Tests
  • Brain (drug effects, metabolism, pathology)
  • Cytokines (blood, drug effects)
  • Dose-Response Relationship, Drug
  • Drug Therapy, Combination
  • Fibrinogen (drug effects, metabolism)
  • Hemorrhage (chemically induced, pathology)
  • Intracranial Hemorrhages (chemically induced, pathology)
  • Kidney (drug effects, metabolism, pathology)
  • Lipopolysaccharides (pharmacology, toxicity)
  • Male
  • Mice
  • Mice, Inbred C57BL (blood)
  • Models, Animal
  • Neutrophils (cytology)
  • Peptide Hydrolases (drug effects)
  • Plasminogen Activator Inhibitor 1 (blood, genetics)
  • Platelet Count
  • RNA, Messenger (metabolism)
  • Shiga Toxin 2 (pharmacology, toxicity)
  • Shock (chemically induced)
  • Thromboplastin (genetics)
  • Time Factors
  • Tissue Distribution

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: